• Regeneron’s Q2 2026 earnings call drew CEO Leonard Schleifer, CSO George Yancopoulos, Commercial EVP Marion McCourt, CFO Christopher Fenimore.
• Revenue rose 17% to USD 4.3 billion; non-GAAP EPS increased 11% to USD 14.29, including a USD 0.99 hit from acquired IPR&D charges.
• EYLEA HD U.S. net sales reached USD 596 million, up 52%; management targeted EYLEA HD prefilled-syringe clearance before year-end using more than two CMOs.
• Sanofi collaboration revenue hit USD 2.2 billion; Fenimore flagged a step-up starting Q3 as the USD 3.1 billion Sanofi development balance was fully repaid.
• Management guided to August FDA action for garetosmab in FOP; November FDA decision for cemdisiran in gMG; PNH registrational readout in Q4.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.